Guggenheim Capital LLC Arcutis Biotherapeutics, Inc. Transaction History

Guggenheim Capital LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$10.23 - $17.14 $2,393 - $4,010	234 Added 2.27%	10,531 $115,000
Q4 2022 Feb 14, 2023	SELL	$13.96 - $20.4 $22,308 - $32,599	-1,598 Reduced 13.43%	10,297 $152,000
Q3 2022 Nov 14, 2022	SELL	$17.85 - $26.95 $2,159 - $3,260	-121 Reduced 1.01%	11,895 $228,000
Q2 2022 Aug 15, 2022	SELL	$16.33 - $22.2 $4,082 - $5,550	-250 Reduced 2.04%	12,016 $256,000
Q1 2022 May 16, 2022	BUY	$14.38 - $22.79 $22,202 - $35,187	1,544 Added 14.4%	12,266 $236,000
Q4 2021 Feb 14, 2022	BUY	$14.98 - $25.5 $160,615 - $273,411	10,722 New	10,722 $222,000

197

129M

738K

82K

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $825M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.